SynthesisPLoS neglected tropical diseases2016
Anti-PGL-1 Positivity as a Risk Marker for the Development of Leprosy among Contacts of Leprosy Cases: Systematic Review and Meta-analysis.
Synthesis in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Self-healing in leprosy: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Factors associated with the development of leprosy in Brazilian contacts: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Pooled it
- Socioeconomic risk markers of leprosy in high-burden countries: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2018Pooled it
- Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh.PLoS neglected tropical diseases · 2017Trial
- Glycosylation profile ofiScience · 2026Article
- Implementation of ML Flow for leprosy contacts in Brazil: Opportunities, pitfalls, and safeguards.PLoS neglected tropical diseases · 2026Review
- Public Health Response to Imported Hansen's Disease Cases and Contact Investigation Findings in the Chungcheong Region, 2024-2025.Public health weekly report · 2026Article
- Peripheral nerve biopsy in pure neural leprosy: a 26-year experience in Brazil.Brain communications · 2026Article
- Article
- Challenges and advances in serological and molecular tests to aid leprosy diagnosis.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Polyunsaturated Fatty Acid-Derived Lipid Mediators as Potential Biomarkers for Leprosy Among Individuals with AsymptomaticACS infectious diseases · 2023Article
- Profile of the leprosy endemic in the district of Murrupula, Nampula, Mozambique: A population-based study.Revista da Sociedade Brasileira de Medicina Tropical · 2023Article
- High-resolution ultrasonography for early diagnosis of neural impairment in seropositive leprosy household contacts.PloS one · 2023Article
- Can anti-PGL-I antibody isotypes differentiate leprosy contacts and leprosy patients?Pathogens and global health · 2022Article
- Peripheral neuropathy in leprosy: Clinical manifestations and disability in a Colombian national referral center.Dermatology reports · 2022Article
- Arginase 1 is a marker of protection against illness in contacts of leprosy patients.Scientific reports · 2022Article
- Serum Interleukin 6 Level and Nutrition Status as Potential Predictors of Clinical Leprosy Development Among Household Contacts in Endemic Areas.Open forum infectious diseases · 2022Article
- A 5-year evaluation of chemoprophylactic treatment in elementary school children with subclinical leprosy.Biomedical reports · 2021Article
- In search of biomarkers for leprosy by unraveling the host immune response to Mycobacterium leprae.Immunological reviews · 2021Review
- Lepra Bubalorum, a Potential Reservoir ofFrontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is no point of care diagnostic test for infection with M. Leprae or for leprosy, although ELISA anti PGL-1 has been considered and sometimes used as a means to identify infection.
methodsA systematic review of all cohort studies, which classified healthy leprosy contacts, at entry, according to anti-PGL1 positivity, and had at least one year follow up. The outcome was clinical diagnosis of leprosy by an experienced physician. The meta-analysis used a fixed model to estimated OR for the association of PGL-1 positivity and clinical leprosy. A fixed model also estimated the sensibility of PGL-1 positivity and positive predictive value.
resultsContacts who were anti PGL-1 positive at baseline were 3 times as likely to develop leprosy; the proportion of cases of leprosy that were PGL-1 positive at baseline varied but was always under 50%.
conclusionsAlthough there is a clear and consistent association between positivity to anti PGL-1 and development of leprosy in healthy contacts, selection of contacts for prophylaxis based on anti PGL1 response would miss more than half future leprosy cases. Should chemoprophylaxis of controls be incorporated into leprosy control programmes, PGL1 appears not to be a useful test in the decision of which contacts should receive chemoprophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.